Cozaar is a medication with the active ingredient losartan. It is also known by its generic name, losartan potassium. Cozaar is mainly used to treat high blood pressure (hypertension) and can also help protect the kidneys in people with diabetes.
The Cozaar price is approximately £0.64 – £1.21 per pills. It depends on the size of the pack and the amount of active ingredient (28 or 360 mg).
Cozaar (Losartan Potassium) is an angiotensin II receptor antagonist, primarily used to treat high blood pressure. By blocking the effects of angiotensin II, it helps relax blood vessels, lowering blood pressure and improving blood flow.
Cozaar is well-absorbed from the gastrointestinal tract, with an oral bioavailability of around 33%. It reaches peak plasma concentrations approximately 1 hour after ingestion. The drug is metabolized in the liver by the cytochrome P450 enzyme system, primarily into an active metabolite, E-3174. The half-life of Losartan is about 2 hours, while the active metabolite has a half-life of approximately 6-9 hours.
The initial recommended dose of Cozaar for adults with hypertension is 50 mg once daily. Depending on the blood pressure response, the dosage may be adjusted to 25 mg to 100 mg daily. In specific scenarios like volume depletion, patients may start at a lower dose of 25 mg once daily. The medication can be taken with or without food.
Common side effects of Cozaar include dizziness, back pain, nasal congestion, electrolyte imbalances, and fatigue. Less common but more severe reactions can include kidney issues, hypotension, and elevated potassium levels in the blood. Regular monitoring of kidney function and electrolytes may be required.
Cozaar may interact with various medications, including diuretics, NSAIDs, potassium supplements, and certain lithium drugs. Combining Cozaar with other blood pressure-lowering agents may cause an additive effect and risk significant drops in blood pressure. Concomitant use with NSAIDs may diminish the antihypertensive effect and increase the risk of renal dysfunction.
In patients with hepatic impairment, dosage adjustments are necessary due to altered drug metabolism. For individuals with renal issues, careful monitoring is recommended, although no initial dosage change is generally required. The safety and efficacy for use in pediatric patients aged 6 years and older are established, though initial dosing for children is determined by weight.
Cozaar functions by selectively blocking the binding of angiotensin II to the AT1 receptor in tissues like vascular smooth muscle and the adrenal gland. This inhibition prevents vasoconstriction and aldosterone-secreting effects of angiotensin II, contributing to a reduction in blood pressure and afterload on the heart.
Clinical trials have demonstrated Cozaar’s effectiveness in managing hypertension and reducing the risk of stroke in patients with left ventricular hypertrophy. Studies also show its effectiveness in slowing the progression of nephropathy in patients with type 2 diabetes and hypertension. The studies highlight favorable effects on cardiovascular morbidity and mortality.
Patients should be instructed on the importance of adherence to prescribed dosing schedules, lifestyle modifications such as diet and exercise, and routine follow-up appointments for blood pressure monitoring. It’s important to inform patients about the potential side effects and the importance of promptly reporting any symptoms like swelling, irregular heartbeat, or difficulty breathing.
Cozaar can cause changes in laboratory test results, including decreased hemoglobin and hematocrit levels. It may also affect kidney function tests, leading to elevated serum creatinine and blood urea nitrogen (BUN) levels. Periodic monitoring of these parameters is recommended during therapy.
Cozaar is available in tablet form in various strengths, including 25 mg, 50 mg, and 100 mg. Tablets are film-coated to improve gastrointestinal tolerance. Prescribers should ensure the accurate dispensing of the correct dosage strength according to the patient’s treatment plan.
Store Cozaar tablets at room temperature, away from excessive moisture, light, and heat. The medication should be kept in its original container until use and kept out of the reach of children. Proper storage conditions are essential to maintain the medication’s efficacy and shelf life.
In cases of Cozaar overdose, symptomatic and supportive measures should be initiated. Patients may exhibit hypotension, tachycardia, or bradycardia. Activated charcoal might be administered if the overdose is recent. Hemodialysis is not effective due to the high degree of Losartan protein binding.
Losartan Potassium, the generic form of Cozaar, is widely available and may offer a cost-effective alternative. It retains the same pharmacological properties and efficacy as the brand-name version. Healthcare providers can provide patients with information regarding generic options to facilitate informed decision-making.
Besides its primary indications, Cozaar has been used off-label for conditions such as heart failure and Marfan syndrome. These off-label uses are based on emerging clinical evidence and should be considered by healthcare professionals on a case-by-case basis. Detailed discussion and thorough understanding are required before initiating off-label use.